3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
32
Metastatic Castration-resistant Prostate Cancer
4
Kidney Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Carcinoma, Renal Cell
2
Urogenital Neoplasms
1
Thrombocytopenia
1
Renal Insufficiency
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Hormone Naive Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
1
Male Urogenital Diseases
1
Liver Neoplasms
1
High-Risk Localized Prostate Cancer
1
Glioma
1
Glioblastoma
1
Genital Neoplasms, Male
1
Disease
1
Cytopenia
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Astrocytoma
1
Anemia
1
Interventions
Radiosurgery
3
Androgen Antagonists
3
Prednisone
2
Docetaxel
2
Abiraterone Acetate
2
fludrocortisone acetate
1
enzalutamide
1
darolutamide
1
apalutamide
1
Standard of Care
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Pluvicto
1
Midazolam
1
Lutetium-177
1
Lutetium
1
Hydrocortisone
1
Gonadotropin-Releasing Hormone
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostate Cancer Metastatic
×
Pluvicto
×
1 year
×
Clear all
NCT06320067
2025-09-26
STAMPEDE2
University College, London
Phase 3
Recruiting
3,360 enrolled